8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 8 of 8 clinical reviews.
A detailed review of dulaglutide (Trulicity) safety signals reported through the FDA Adverse Event Reporting System (FAERS), including gastrointestinal events, pancreatitis, thyroid concerns, and cardiovascular outcomes from the REWIND trial.
Complete FDA approval history of Trulicity (dulaglutide), including original 2014 approval, CVOT-driven label expansions, boxed warning details, and post-market safety signals from FAERS and Sentinel.
A complete regulatory overview of Trulicity (dulaglutide), covering FDA approval, EMA authorization, label expansions, REWIND cardiovascular data, post-market safety signals, and current global market access.
A clinical review of Trulicity's regulatory timeline, patent disputes, Paragraph IV litigation, and post-market safety actions that shape dulaglutide access in 2026.
A complete regulatory and clinical reference for dulaglutide (Trulicity): FDA approval history, label updates, post-market safety data from REWIND, and how Lilly's next-generation GLP-1 pipeline positions against it.
A complete regulatory guide to Trulicity (dulaglutide) compounding legal status, FDA approval history, label requirements, and post-market safety data. Reviewed by the HealthRX.com medical team.
A detailed comparison of how the FDA and EMA evaluated, approved, and monitor dulaglutide (Trulicity), including label differences, post-market obligations, and what each framework means for patients and prescribers.
Every FDA label change for Trulicity (dulaglutide) from 2020 through 2026, including the REWIND cardiovascular indication, boxed warning revisions, and post-market safety signals.